MRNAModerna

1. Sep 1, 2026Indenture and Notes On September 1, 2026, Moderna, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $3,000,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the initial purchasers’ option to …Material agreement entered · Form 8-K
2. Jul 31, 2026Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
3. Jul 8, 2026On July 6, 2026, the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), appointed Michael McDonnell to the Board, effective July 8, 2026.Director or officer change · Form 8-K
4. May 11, 2026On May 6, 2026, the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated By-Laws (the “By-Law Amendment”), effective immediately, to designate the federal district courts of the United States as the sole and exclusive forum for resolving …Charter/bylaw amendment or fiscal-year change · Form 8-K
5. May 1, 2026Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
6. Mar 5, 2026On March 3, 2026 (the “Effective Date”), Moderna, Inc. (the “Company”) and ModernaTX, Inc. (together with the Company, “Moderna”) and Arbutus Biopharma Corporation (“Arbutus”), Genevant Sciences GmbH (“Genevant” and, together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd. …Material agreement entered · Form 8-K
7. Feb 13, 2026Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates.Earnings release · press release
8. Feb 11, 2026On February 3, 2026, the FDA's Center for Biologics Evaluation and Research (“CBER”) notified the Company that it will not initiate a review of the biologics license application (“BLA”) for the Company's investigational influenza vaccine, mRNA-1010, and has issued a Refusal-to-File letter.Regulation FD disclosure · Form 8-K
9. Jan 12, 2026Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference.Earnings release · press release
10. Nov 24, 2025On November 19, 2025, Moderna, Inc. (the “Company”) entered into a Credit and Guaranty Agreement (the “Credit Agreement”), among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.